Literature DB >> 19428206

Dose-dependent effect of risperidone treatment in a case of 22q13.3 deletion syndrome.

Augusto Pasini1, Elisa D'Agati, Livia Casarelli, Paolo Curatolo.   

Abstract

We describe a 18-year-old female with 22q13.3 deletion syndrome characterized by an alteration of SHANK3/PROSAP2 and severe mental retardation, intense psychomotor agitation and aggressive behaviour. When the patient was given risperidone, different therapeutic results were observed: at a 6 mg dose, risperidone had no therapeutic effect and the patient's behavioural problems increased; at a low dose (1mg), risperidone treatment resulted in rapid improvement of mood and behaviour. Recent findings suggest that risperidone exerts dose-dependent effects on Glu receptors in developing rats. An altered preset of the glutamate receptors, due to the presence of a haploinsufficiency of SHANK3/PROSAP2, could explain the different results of risperidone therapy observed in our patient with 22q13.3 deletion syndrome. Copyright 2009 Elsevier B.V. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19428206     DOI: 10.1016/j.braindev.2009.04.005

Source DB:  PubMed          Journal:  Brain Dev        ISSN: 0387-7604            Impact factor:   1.961


  7 in total

Review 1.  Phelan-McDermid Syndrome and SHANK3: Implications for Treatment.

Authors:  Jesse L Costales; Alexander Kolevzon
Journal:  Neurotherapeutics       Date:  2015-07       Impact factor: 7.620

2.  The 22q13.3 Deletion Syndrome (Phelan-McDermid Syndrome).

Authors:  K Phelan; H E McDermid
Journal:  Mol Syndromol       Date:  2011-11-22

Review 3.  Comparison of SHANK3 deficiency in animal models: phenotypes, treatment strategies, and translational implications.

Authors:  Jan Philipp Delling; Tobias M Boeckers
Journal:  J Neurodev Disord       Date:  2021-11-16       Impact factor: 4.025

4.  Adult-onset psychosis and clinical genetics: a case of Phelan-McDermid syndrome.

Authors:  Erick Messias; Sean N Kaley; Kent D McKelvey
Journal:  J Neuropsychiatry Clin Neurosci       Date:  2013       Impact factor: 2.198

5.  A pilot controlled trial of insulin-like growth factor-1 in children with Phelan-McDermid syndrome.

Authors:  Alexander Kolevzon; Lauren Bush; A Ting Wang; Danielle Halpern; Yitzchak Frank; David Grodberg; Robert Rapaport; Teresa Tavassoli; William Chaplin; Latha Soorya; Joseph D Buxbaum
Journal:  Mol Autism       Date:  2014-12-12       Impact factor: 7.509

6.  Neuropsychiatric decompensation in adolescents and adults with Phelan-McDermid syndrome: a systematic review of the literature.

Authors:  Alexander Kolevzon; Elsa Delaby; Elizabeth Berry-Kravis; Joseph D Buxbaum; Catalina Betancur
Journal:  Mol Autism       Date:  2019-12-24       Impact factor: 7.509

7.  Synergistic inhibition of histone modifiers produces therapeutic effects in adult Shank3-deficient mice.

Authors:  Freddy Zhang; Benjamin Rein; Ping Zhong; Treefa Shwani; Megan Conrow-Graham; Zi-Jun Wang; Zhen Yan
Journal:  Transl Psychiatry       Date:  2021-02-04       Impact factor: 6.222

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.